Work

Artificial Intelligence for Cardiovascular Health in China

Year: 2026
Type: article
Abstract: C ardiovascular disease (CVD) burden in China is mainly driven by the large population and rapid population aging.As of 2021, China's CVD mortality rate (357.4 per 100,000 persons) is higher than the global average (258.8 per 100,000 persons) and contributed to a 103.7% increase in absolute deaths over the past 3 decades, marked by disparities across sexes and provinces.1 Simultaneously, China has made advancements in the medical artificial intelligence (AI) field, evidenced by a growing number of AI-related medical publications and early clinical applications.2 However, despite rapid improvements in medical AI performance, its clinical translation in cardiovascular care remains at an exploration stage.3 The gap between AI model performance and real-world implementation is particularly pronounced in China, which has a large and aging population, marked regional disparities, and a tiered health care system.The Chinese Academy of Sciences and major universities with top-tier affiliated hospitals in China play a pivotal role in bridging the gap between technical innovation and clinical research in cardiovascular health.4 To inform researchers and health care providers the advance knowledge about AI-enable CVD management, we summarize the landscape and challenges of AI for cardiovascular health in China (Figure 1).LANDSCAPE OF AI FOR CARDIOVASCULAR HEALTH IN CHINA AI-enabled tools are increasingly being introduced into cardiovascular care in China, spanning research and innovation, screening and prevention, diagnosis and treatment, telemedicine and follow-up, under the national policy and governance.In total, medical AI in China is moving beyond technical proof-ofconcept toward broader clinical translation for CVD management.
Source: JACC Asia
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,084
OpenAlex ID: W7163750789
FWCI:
Cites: 18
Cited by:
Related to: 10